ArticleJournal of gastrointestinal oncology2017
Inflammatory bowel diseases activity in patients undergoing pelvic radiation therapy.
Article in Journal of gastrointestinal oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.
- Radiation Therapy for Abdominal or Pelvic Cancer Treatment in Patients with Inflammatory Bowel Disease: A Systematic Review.Digestive diseases and sciences · 2025Pooled it
- Safety of Radiation Therapy in Patients With Prostate Cancer and Inflammatory Bowel Disease: A Systematic Review.Practical radiation oncologyPooled it
- Organ Preservation After Total Neoadjuvant Therapy in a Patient With Low Rectal Adenocarcinoma and Crohn's Disease.ACG case reports journal · 2026Article
- PTCOG Gastrointestinal Subcommittee Lower Gastrointestinal Tract Malignancies Consensus Statement.International journal of particle therapy · 2024Review
- Safety of high-dose-rate brachytherapy in patients with prostate cancer and inflammatory bowel disease: A case series.Journal of contemporary brachytherapy · 2024Article
- Rectal Cancer and Radiation in Colitis.Clinics in colon and rectal surgery · 2024Review
- Risk of Cancer in Inflammatory Bowel Disease and Pitfalls in Oncologic Therapy.Journal of gastrointestinal cancer · 2023Review
- Inflammatory bowel disease-associated malignancies and considerations for radiation impacting bowel: a scoping review.Journal of gastrointestinal oncology · 2022Article
- Stereotactic body radiation therapy for the treatment of localized prostate cancer in men with underlying inflammatory bowel disease.Radiation oncology (London, England) · 2021Article
- Ulcerative colitis that developed during radiotherapy for prostate cancer, deteriorated rapidly and required emergency surgery.Surgical case reports · 2020Article
- The Complex Interplay Between Inflammatory Bowel Disease and Malignancy.Current gastroenterology reports · 2020Review
- SpaceOAR to improve dosimetric outcomes for monotherapy high-dose-rate prostate implantation in a patient with ulcerative colitis.Journal of contemporary brachytherapy · 2018Article
- Markers of Toxicity and Response to Radiation Therapy in Patients With Prostate Cancer.Advances in radiation oncologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFew studies with contradictory results have been published on the safety of pelvic radiation therapy (RT) in patients with inflammatory bowel disease (IBD).
methodsFrom 1989 to 2015, a single center retrospective analysis was performed including all IBD patients who received pelvic external beam radiation therapy (EBRT) or brachytherapy (BT) for a pelvic malignancy. Treatment characteristics, IBD activity and gastrointestinal (GI) toxicity were examined.
resultsOverall, 28 patients with Crohn's disease (CD) (n=13) or ulcerative colitis (n=15) were included in the present study. Median follow-up time after irradiation was 5.9 years. Regarding IBD activity, only one and two patients experienced a severe episode within and after 6 months of follow-up, respectively. Grade 3/4 acute GI toxicity occurred in 3 (11%) patients, whereas one (3.6%) patient experienced late grade 3/4 GI toxicity. Only patients with rectal IBD location (P=0.016) or low body mass index (BMI) (P=0.012) experienced more severe IBD activity within or after 6 months following RT, respectively.
conclusionsWe report an acceptable tolerance of RT in IBD patients with pelvic malignancies. Specifically, a low risk of uncontrolled flare-up was observed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.